New combo therapy targets hard-to-treat liver metastases in colorectal cancer

This trial tests a personalized treatment plan for people with advanced colorectal cancer that has spread to the liver and stopped responding to standard treatments. The approach combines a liver-directed chemotherapy (HAIC), a targeted therapy (fruquintinib or cetuximab), and an immunotherapy drug (tislelizumab). The study aims to see if this combination can help control the cancer for at least 6 months. It includes 47 participants whose tumors are microsatellite stable (MSS), a type that typically does not respond well to immunotherapy alone.